TAYSHA GENE THERAPIES INC (TSHA) Stock Price, Quote, News and Overview
NASDAQ:TSHA - Nasdaq - US8776191061 - Common Stock - Currency: USD
TSHA Quote, Performance and Key Statistics
NASDAQ:TSHA (4/21/2025, 12:10:03 PM)
1.445
+0.21 (+16.53%)
The current stock price of TSHA is 1.445 USD. In the past month the price decreased by -27.06%. In the past year, price decreased by -45.37%.
TSHA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.84 | 301.45B | ||
| AMGN | AMGEN INC | 13.83 | 147.39B | ||
| GILD | GILEAD SCIENCES INC | 22.57 | 129.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1663.14 | 123.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.33 | 61.50B | ||
| ARGX | ARGENX SE - ADR | 324.7 | 36.88B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.39B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.89B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.65B | ||
| NTRA | NATERA INC | N/A | 19.38B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.51B | ||
| BIIB | BIOGEN INC | 7.07 | 17.05B |
Related stock screener links
About TSHA
Company Profile
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 73 full-time employees. The company went IPO on 2020-09-24. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The firm is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. The company has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). The company received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.
Company Info
TAYSHA GENE THERAPIES INC
3000 Pegasus Park Drive, Suite 1430
Dallas TEXAS 75247 US
CEO: RA Session
Employees: 52
Company Website: https://tayshagtx.com/
Investor Relations: https://ir.tayshagtx.com/
Phone: 12146120000
TAYSHA GENE THERAPIES INC / TSHA FAQ
What is the stock price of TAYSHA GENE THERAPIES INC today?
The current stock price of TSHA is 1.445 USD. The price increased by 16.53% in the last trading session.
What is the ticker symbol for TAYSHA GENE THERAPIES INC stock?
The exchange symbol of TAYSHA GENE THERAPIES INC is TSHA and it is listed on the Nasdaq exchange.
On which exchange is TSHA stock listed?
TSHA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TAYSHA GENE THERAPIES INC stock?
17 analysts have analysed TSHA and the average price target is 6.68 USD. This implies a price increase of 362.35% is expected in the next year compared to the current price of 1.445. Check the TAYSHA GENE THERAPIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TAYSHA GENE THERAPIES INC worth?
TAYSHA GENE THERAPIES INC (TSHA) has a market capitalization of 296.23M USD. This makes TSHA a Micro Cap stock.
How many employees does TAYSHA GENE THERAPIES INC have?
TAYSHA GENE THERAPIES INC (TSHA) currently has 52 employees.
What are the support and resistance levels for TAYSHA GENE THERAPIES INC (TSHA) stock?
TAYSHA GENE THERAPIES INC (TSHA) has a support level at 1.22 and a resistance level at 1.29. Check the full technical report for a detailed analysis of TSHA support and resistance levels.
Is TAYSHA GENE THERAPIES INC (TSHA) expected to grow?
The Revenue of TAYSHA GENE THERAPIES INC (TSHA) is expected to decline by -18.73% in the next year. Check the estimates tab for more information on the TSHA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TAYSHA GENE THERAPIES INC (TSHA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TSHA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TSHA, evaluating the profitability, health, valuation and growth aspects
- TAYSHA GENE THERAPIES INC (TSHA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TAYSHA GENE THERAPIES INC (TSHA) Sales and EPS estimates to see what analysts future expectations are.
- TAYSHA GENE THERAPIES INC (TSHA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TAYSHA GENE THERAPIES INC (TSHA) Insider and Institutional Ownership to learn about the owners and their transactions.
- TAYSHA GENE THERAPIES INC (TSHA) Stock Chart to make your own analysis
- TAYSHA GENE THERAPIES INC (TSHA) Latest news and press-releases to stay up to date.
Does TAYSHA GENE THERAPIES INC (TSHA) stock pay dividends?
TSHA does not pay a dividend.
When does TAYSHA GENE THERAPIES INC (TSHA) report earnings?
TAYSHA GENE THERAPIES INC (TSHA) will report earnings on 2025-05-07, after the market close.
What is the Price/Earnings (PE) ratio of TAYSHA GENE THERAPIES INC (TSHA)?
TAYSHA GENE THERAPIES INC (TSHA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.36).
What is the Short Interest ratio of TAYSHA GENE THERAPIES INC (TSHA) stock?
The outstanding short interest for TAYSHA GENE THERAPIES INC (TSHA) is 15.25% of its float. Check the ownership tab for more information on the TSHA short interest.
TSHA Technical Analysis
TSHA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TSHA. TSHA has a bad profitability rating. Also its financial health evaluation is rather negative.
TSHA Financial Highlights
Over the last trailing twelve months TSHA reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS decreased by -376.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.68% | ||
| ROE | -124.85% | ||
| Debt/Equity | 0.61 |
TSHA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to TSHA. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of -4.65% and a revenue growth -18.73% for TSHA